GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
1. Hu L, Magesh S, Chen L, Wang L, Lewis TA, Chen Y, Khodier C, Inoyama D, Beamer LJ, Emge TJ et al.. (2013) Discovery of a small-molecule inhibitor and cellular probe of Keap1-Nrf2 protein-protein interaction. Bioorg Med Chem Lett, 23 (10): 3039-43. [PMID:23562243]
2. Jiang ZY, Xu LL, Lu MC, Chen ZY, Yuan ZW, Xu XL, Guo XK, Zhang XJ, Sun HP, You QD. (2015) Structure-Activity and Structure-Property Relationship and Exploratory in Vivo Evaluation of the Nanomolar Keap1-Nrf2 Protein-Protein Interaction Inhibitor. J Med Chem, 58 (16): 6410-21. [PMID:26258437]
3. Krajka-Kuźniak V, Paluszczak J, Baer-Dubowska W. (2017) The Nrf2-ARE signaling pathway: An update on its regulation and possible role in cancer prevention and treatment. Pharmacol Rep, 69 (3): 393-402. [PMID:28267640]
4. Lu MC, Ji JA, Jiang YL, Chen ZY, Yuan ZW, You QD, Jiang ZY. (2016) An inhibitor of the Keap1-Nrf2 protein-protein interaction protects NCM460 colonic cells and alleviates experimental colitis. Sci Rep, 6: 26585. [PMID:27215610]
5. Lu MC, Ji JA, Jiang ZY, You QD. (2016) The Keap1-Nrf2-ARE Pathway As a Potential Preventive and Therapeutic Target: An Update. Med Res Rev, 36 (5): 924-63. [PMID:27192495]
6. Magesh S, Chen Y, Hu L. (2012) Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents. Med Res Rev, 32 (4): 687-726. [PMID:22549716]
To cite this family introduction, please use the following:
Kelch-like proteins, introduction. Last modified on 27/02/2018. Accessed on 04/07/2025. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetopharmacology.org/GRAC/FamilyIntroductionForward?familyId=876.